Skip to main content
. 2025 Aug 19;36(3):102689. doi: 10.1016/j.omtn.2025.102689

Figure 2.

Figure 2

Increased kidney and circulating MALAT1 levels in fibrotic kidney disease

(A) Quantitative reverse-transcription PCR (RT-qPCR) analysis of MALAT1 levels in plasma of patients with diabetic kidney disease (DKD, n = 11) and healthy controls (n = 12); student’s t test. (B) RT-qPCR analysis of MALAT1 in extracellular vesicles from HUVECs stimulated with TGF-β and/or TNF-α or vehicle control (n = 3); one-way ANOVA. (C) MALAT1 expression levels in fibrotic kidney tissue compared to controls from different datasets. IFTA, interstitial fibrosis and tubular atrophy; CKD, chronic kidney disease. ∗p < 0.05 and ∗∗p < 0.01.